THE NEXT EVOLUTION IN TARGETED ONCOLOGY
While targeted therapies have revolutionized cancer care, their efficacy is frequently compromised by a narrow therapeutic window, where the dose required to kill a tumor often causes intolerable systemic side effects. Cuttlefish Bio is bridging this gap by engineering a platform that decouples targeting from toxicity, ensuring that potent therapeutic activity is restricted exclusively to the tumor microenvironment.
THE LOCAL FACTORY
We deliver a highly specific antibody-directed enzyme (ADE) with finely tuned enzymatic activity to the tumor site first.
ON-DEMAND ACTIVATION
Once the enzyme is docked at the site of the tumour and systemic enzyme has dissipated, a separately administered, non-toxic prodrug is introduced.
LOCALIZED KILLING
The enzyme acts as a site-specific catalyst, converting the prodrug into a potent cell-killing payload exactly where it is needed.